Table 3.
Recurrence-free survival and overall survival in intrahepatic cholangiocarcinoma.
| RFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | |||||
| Variables | HR (95%Cl) | p | HR (95%Cl) | p | HR (95%Cl) | p | HR (95%CI) | p |
| Sex (male = 1) | 1.034 (0.688–1.554) | 0.871 | 0.730 (0.502–1.602) | 0.100 | ||||
| Age, years (≤65 = 1) |
0.769 (0.510–1.159) | 0.209 | 1.544 (1.061–2.247) | 0.023 | 1.564 (0.894–2.736) | 0.117 | ||
| ASA (I/II = 1) | 1.131 (0.753–1.699) | 0.554 | 0.730 (0.502–1.602) | 0.100 | ||||
| Cholangitis (no = 1) |
0.266 (0.065–1.085) | 0.065 | 0.238 (0.057–1.044) | 0.049 | 1.544 (1.061–2.247) | 0.023 | 1.077 (0.414–2.804) | 0.879 |
| PVE (no = 1) | 1.496 (0.750–2.987) | 0.253 | 1.714 (0.937–3.135) | 0.080 | 1.878 (0.746–4.727) | 0.181 | ||
| Neoadjuvant therapy (no = 1) | 2.271 (1.270–4.061) | 0.006 | 3.607 (1.758–7.402) | <0.001 | 1.907 (1.112–3.270) | 0.019 | 1.771 (0.554–5.659) | 0.575 |
| AST, U/L (≤40 = 1) |
1.264 (0.829–1.927) | 0.277 | 1.108 (0.751–1.633) | 0.606 | ||||
| ALT, U/L (≤40 = 1) |
1.186 (0.743–1.892) | 0.474 | 1.090 (0.705–1.685) | 0.697 | ||||
| AP, U/L (≤100 = 1) |
1.829 (1.177–2.842) | 0.007 | 1.218 (0.652–2.278) | 0.536 | 1.958 (1.276–3.005) | 0.002 | 1.193 (0.589–2.416) | 0.624 |
| CRP, mg/L (≤8.2 = 1) |
2.319 (1.513–3.555) | <0.001 | 2.190 (1.232–3.894) | 0.008 | 2.308 (1.379–3.012) | <0.001 | 1.747 (0.815–3.746) | 0.152 |
| GGT, U/L (≤100 = 1) |
1.751 (1.155–2.654) | 0.008 | 1.124 (0.620–2.039) | 0.700 | 1.691 (1.147–2.493) | 0.008 | 1.189 (0.612–2.308) | 0.610 |
| Hemoglobin, g/dL (≤13 = 1) | 0.637 (0.423–0.960) | 0.031 | 0.901 (0.515–1.576) | 0.715 | 0.595 (0.409–0.868) | 0.007 | 0.410 (0.243–0.693) | 0.001 |
| INR (≤1 = 1) | 1.497 (0.990–2.265) | 0.056 | 1.603 (0.970–2.648) | 0.065 | 1.380 (0.946–2.013) | 0.095 | 1.030 (0.573–1.851) | 0.921 |
| Platelet count, L/nL (≤300 = 1) | 1.499 (0.965–2.330) | 0.072 | 1.008 (0.587–1.731) | 0.977 | 0.901 (0.591–1.374) | 0.629 | ||
| Prothrombin time (≤110 = 1) | 0.761 (0.448–1.292) | 0.312 | 0.643 (0.386–1.070) | 0.089 | 0.804 (0.348–1.855) | 0.609 | ||
| Bilirubin, mg/dL (≤1 = 1) | 0.789 (0.420–1.483) | 0.462 | 1.229 (0.740–2.041) | 0.425 | ||||
| Intraoperative PRBC (No = 1) | 1.906 (1.235–2.942) | 0.004 | 1.379 (0.756–2.515) | 0.295 | 2.001 (1.366–2.930) | <0.001 | 0.726 (0.307–1.714) | 0.465 |
| Intraoperative FFP (No = 1) | 1.687 (1.104–2.578) | 0.016 | 1.274 (0.785–2.066) | 0.327 | 1.986 (1.365–2.890) | <0.001 | 2.546 (1.449–4.473) | 0.001 |
| Operative time, min (≤360 = 1) | 1.562 (0.993–2.459) | 0.054 | 1.028 (0.574–1.839) | 0.926 | 1.988 (1.324–2.986) | 0.001 | 1.680 (0.883–3.199) | 0.114 |
| Time to surgery, days (≤30 = 1) | 0.704 (0.451–1.097) | 0.120 | 1.022 (0.698–1.497) | 0.911 | ||||
| LVI (no = 1) | 2.600 (1.569–4.309) | <0.001 | 2.399 (1.316–4.373) | 0.004 | 3.416 (2.208–5.285) | <0.001 | 3.920 (2.197–6.992) | < 0.001 |
| MVI (no = 1) | 1.027 (0.956–1.103) | 0.470 | 1.038 (1.016–1.061) | 0.001 | 1.034 (1.006–1.062) | 0.015 | ||
| R1 resection (R0/Rx = 1) | 1.992 (1.045–3.764) | 0.036 | 1.290 (0.524–3.174) | 0.579 | 1.768 (0.984–3.176) | 0.056 | 1.290 (0.455–3.659) | 0.632 |
| pT category (T1/T2 = 1) |
1.341 (0.836–2.152) | 0.224 | 1.674 (1.099–2.550) | 0.016 | 1.291 (0.684–2.435) | 0.431 | ||
| pN category (N0 = 1) |
2.871 (1.828–4.511) | <0.001 | 1.525 (0.809–2.878) | 0.192 | 3.320 (2.198–5.015) | <0.001 | 1.195 (0.487–2.934) | 0.697 |
| Tumor grading (G1/G2 = 1) | 1.441 (0.895–2.318) | 0.133 | 2.118 (1.389–3.230) | <0.001 | 2.138 (1.272–3.594) | 0.004 | ||
| ICU time, days (≤1 = 1) |
1.122 (0.669–1.879) | 0.663 | 1.579 (1.013–2.459) | 0.044 | 1.052 (0.502–2.203) | 0.894 | ||
| Hospitalization, days (≤14 = 1) | 1.023 (2.308–) | 0.038 | 1.036 (0.541–1.985) | 0.915 | 1.567 (1.079–2.277) | 0.018 | 1.024 (0.520–2.019) | 0.944 |
| Perioperative complications (Clavien–Dindo 0/I/II = 1) | 1.7533 (1.159–2.653) | 0.008 | 1.631 (0.900–2.957) | 0.107 | 2.230 (1.532–3.247) | <0.001 | 3.776 (1.617–8.817) | 0.002 |
| Liver failure (no = 1) |
1.597 (0.902–2.830) | 0.108 | 1.815 (1.153–2.858) | 0.010 | 1.144 (0.611–2.142) | 0.674 | ||
| Bile leak (no = 1) |
1.377 (0.811–2.338) | 0.236 | 1.809 (1.135–2.883) | 0.013 | 1.082 (0.483–2.420) | 0.849 | ||
| Hemorrhage (No = 1) |
0.928 (0.377–2.286) | 0.871 | 2.304 (1.055–3.919) | 0.034 | 1.850 (0.668–5.122) | 0.236 | ||
| Infection complications (Clavien–Dindo 0/I/II = 1) | 2.256 (1.421–3.580) | 0.001 | 1.658 (0.955–2.878) | 0.073 | 2.438 (1.624–3.660) | <0.001 | 1.545 (0.655–3.641) | 0.320 |
| Adjuvant therapy (no = 1) |
1.145 (0.759–1.728) | 0.518 | 0.620 (0.406–0.948) | 0.010 | 0.273 (0.149–0.500) | <0.001 | ||
| BMI, kg/m2
(≤25 = 1) |
0.855 (0.571–1.282) | 0.450 | 0.913 (0.629–1.326) | 0.632 | ||||
| Visceral_fat area (≤100 = 1) |
0.731 (0.487–1.098) | 0.131 | 1.067 (0.726–1.568) | 0.741 | ||||
| Sarcopenia (no = 1) |
0.890 (0.587–1.349) | 0.586 | 1.509 (1.027–2.217) | 0.036 | 1.293 (0.640–2.613) | 0.474 | ||
| Myosteatosis (no = 1) |
0.829 (0.553–1.245) | 0.367 | 1.200 (0.817–1.762) | 0.352 | ||||
| Sarcopenic_obesity (no = 1) | 0.932 (0.528–1.646) | 0.808 | 1.267 (0.742–2.165) | 0.386 | ||||
Multiple variables were associated with recurrence-free and overall survival. Variables displaying a p-value < 0.1 in the univariate Cox regression were transferred into a multivariable Cox regression model. The table heading is shown in grey background. ALT, alanine aminotransferase; ASA, American Society of Anesthesiologists; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; FFP, fresh frozen plasma; GGT, gamma-glutamyl transferase; HR, hazard ratio; ICU, intensive care unit; INR, international normalized ratio; LVI, lymph vascular invasion; MVI, microvascular invasion; PVE, portal vein embolization; RFS, recurrence-free survival.